Holen Sie sich die Stockscreener-App
3.84
8.17%
0.29
Vorhandelsmarkt:
3.83
-0.010
-0.26%
Schlusskurs vom Vortag:
$3.55
Offen:
$3.52
24-Stunden-Volumen:
2.10M
Relative Volume:
0.53
Marktkapitalisierung:
$345.50M
Einnahmen:
$324.00K
Nettoeinkommen (Verlust:
$-82.10M
KGV:
-4.129
EPS:
-0.93
Netto-Cashflow:
$-69.18M
1W Leistung:
+13.95%
1M Leistung:
+28.43%
6M Leistung:
+326.71%
1J Leistung:
+315.36%
1-Tages-Spanne:
$3.4301
$4.07
1-Wochen-Bereich:
$3.25
$4.07
52-Wochen-Spanne:
$0.75
$4.07
Chimerix Inc Stock (CMRX) Company Profile
Firmenname
Chimerix Inc
Sektor
Branche
Telefon
919.806.1074
Adresse
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC
Vergleichen Sie CMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMRX
Chimerix Inc
|
3.84 | 345.50M | 324.00K | -82.10M | -69.18M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Chimerix Inc Stock (CMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-05-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-09-07 | Eingeleitet | CapitalOne | Overweight |
| 2021-04-29 | Eingeleitet | Maxim Group | Buy |
| 2021-04-23 | Fortgesetzt | Cowen | Outperform |
| 2021-03-31 | Eingeleitet | Jefferies | Buy |
| 2021-03-31 | Eingeleitet | Wedbush | Outperform |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-02-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-09 | Bestätigt | FBR Capital | Mkt Perform |
| 2016-02-23 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2016-02-23 | Bestätigt | FBR Capital | Mkt Perform |
| 2016-02-23 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2016-02-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2015-12-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-12-28 | Herabstufung | FBR Capital | Outperform → Mkt Perform |
| 2015-12-28 | Bestätigt | Piper Jaffray | Overweight |
| 2015-12-17 | Eingeleitet | UBS | Buy |
| 2015-10-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2015-09-03 | Eingeleitet | Citigroup | Buy |
| 2015-08-18 | Eingeleitet | FBR Capital | Outperform |
| 2015-08-06 | Bestätigt | Brean Capital | Buy |
| 2015-05-11 | Bestätigt | Brean Capital | Buy |
| 2015-03-04 | Eingeleitet | Barclays | Overweight |
| 2015-02-12 | Bestätigt | Stifel | Buy |
| 2014-12-31 | Bestätigt | Brean Capital | Buy |
| 2014-07-08 | Fortgesetzt | Brean Capital | Buy |
Alle ansehen
Chimerix Inc Aktie (CMRX) Neueste Nachrichten
Assenagon Asset Management S.A. Has $2.85 Million Holdings in Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Chimerix stock soars to 52-week high, hits $3.8 - MSN
Here’s Why Chimerix, Inc. (CMRX) Is Skyrocketing - MSN
Chimerix, Inc. (NASDAQ:CMRX) Sees Large Decline in Short Interest - MarketBeat
Why These 24 Stocks Are Skyrocketing - Insider Monkey
Chimerix to Speak Today at The White House Cancer Moonshot Forum - The Manila Times
Chimerix CSO to Present at Biden Cancer Moonshot Forum on Breakthrough Brain Cancer Treatment - StockTitan
Geode Capital Management LLC Trims Holdings in Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Chimerix stock soars to 52-week high, hits $3.73 By Investing.com - Investing.com South Africa
Chimerix (NASDAQ:CMRX) Shares Pass Above 50-Day Moving AverageHere's What Happened - MarketBeat
Chimerix stock soars to 52-week high, hits $3.73 - Investing.com
Chimerix asks FDA to approve oral dordaviprone as glioma treatment - Myeloma Research News
H.C. Wainwright reiterates Buy rating on Chimerix stock amid NDA submission for ONC201 - Investing.com Canada
Buy rating reaffirmed on Chimerix stock with potential 3Q25 launch for ONC201 - Investing.com Australia
Buy rating reaffirmed on Chimerix stock with potential 3Q25 launch for ONC201 By Investing.com - Investing.com South Africa
Chimerix (NASDAQ:CMRX) Given Buy Rating at HC Wainwright - Defense World
Chimerix (NASDAQ: CMRX) Enters Amended Loan Agreement with Silicon Valley Bank - Defense World
Chimerix takes pivotal step for novel brain cancer drug - The Business Journals
A Glimpse Into The Expert Outlook On Chimerix Through 4 Analysts - Benzinga
Chimerix's (CMRX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Chimerix, Inc. Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma - Marketscreener.com
Chimerix (CMRX) Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma - StreetInsider.com
Chimerix Files FDA Application for Novel Brain Cancer Drug Dordaviprone, Secures $30M Launch Funding - StockTitan
Chimerix stock soars to 52-week high, hits $3.44 By Investing.com - Investing.com Nigeria
Chimerix stock soars to 52-week high, hits $3.44 - Investing.com India
Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update - MarketBeat
Chimerix, Inc. (NASDAQ:CMRX) Sees Significant Drop in Short Interest - MarketBeat
Biodefense Market CAGR of 7.3% Size, Growth Drivers and Forecast 2024-2031 | XOMA corporation, Altimmune Inc., - EIN News
Wedbush Weighs in on Chimerix’s Q4 Earnings (NASDAQ:CMRX) - Defense World
HC Wainwright Has Positive Outlook of Chimerix Q4 Earnings - Defense World
HC Wainwright Has Bullish Forecast for Chimerix Q4 Earnings - MarketBeat
Drugmaker seeks accelerated breakthrough for brain cancer treatment - The Business Journals
Wedbush Analysts Reduce Earnings Estimates for Chimerix - MarketBeat
Wedbush Brokers Lower Earnings Estimates for Chimerix - MarketBeat
3 Penny Stocks to Watch Now, 12/12/24 - TipRanks
Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy (NASDAQ:CMRX) - Seeking Alpha
Chimerix (NASDAQ:CMRX) Earns Buy Rating from HC Wainwright - MarketBeat
Chimerix stock touches 52-week high at $2.20 amid market fluctuations - Investing.com Canada
Chimerix Stock Draws Heavy Retail Chatter After Landing Price-Target Hike On FDA Submission Plan For Cancer Dr - Asianet Newsable
Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Can - GuruFocus.com
3 Promising Penny Stocks With Market Caps Under $2B In US - Simply Wall St
S&P 500 Edges Lower; AutoZone Posts Downbeat EarningsAutoZone (NYSE:AZO), Chimerix (NASDAQ:CMRX) - Benzinga
Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Cancer Therapy - Yahoo Finance
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings - Benzinga
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday? - AOL
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Finanzdaten der Chimerix Inc-Aktie (CMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):